Prescient Therapeutics Ltd.
- Country
- 🇦🇺Australia
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 1
- Market Cap
- -
- Website
- https://ptxtherapeutics.com/
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Prescient Therapeutics, Ltd.
- Target Recruit Count
- 115
- Registration Number
- NCT06854653
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Cente, Duarte, California, United States
🇺🇸University of California Irvine, Irvine, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Prescient Therapeutics, Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT03900442
- Locations
- 🇦🇺
Epworth Healthcare, Melbourne, Victoria, Australia
A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Prescient Therapeutics, Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT02930109
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Kansas Cancer Center, Fairway, Kansas, United States
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
- Conditions
- Breast AdenocarcinomaStage IIIA Breast CancerStage IIIB Breast CancerEstrogen Receptor PositiveHER2/Neu NegativeStage IIIC Breast CancerStage IV Breast CancerRecurrent Breast CarcinomaStage IIB Breast Cancer
- Interventions
- Other: Laboratory Biomarker AnalysisProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Prescient Therapeutics, Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT01697293
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Albert Einstein College of Medicine, Bronx, New York, United States
PTX-200 and Carboplatin in Ovarian Cancer
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Prescient Therapeutics, Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT01690468
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
- Prev
- 1
- 2
- Next